ENOV Stock Analysis: Buy, Sell, or Hold?
ENOV - Enovis Corporation
$21.69
-0.13 (-0.60%)
▼
5d:
-3.64%
30d:
-14.84%
90d:
-20.81%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When ENOV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ENOV appears deeply undervalued. Market expects -7.9% annual earnings decline despite 153% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: ENOV appears deeply undervalued. Market expects -7.9% annual earnings decline despite 153% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$38.90
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$24.16
10.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ENOV is currently trading at $21.69, which is considered oversold relative to its 30-day fair value range of $22.24 to $24.78. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.5) compared to its historical average (7.0). Remarkably, the market is currently pricing in an annual earnings decline of 7.9% over the next few years. This pessimistic expectation contrasts with the company's recent 153.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ENOV is in a strong downtrend. The price is currently testing key support at $21.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $45.18 (+108.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ENOV is in a strong downtrend. The price is currently testing key support at $21.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $45.18 (+108.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$22.24 -
$24.78
Company Quality Score
58/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
77.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 108.3% below Wall St target ($45.18)
Fair Price Analysis
30-Day Fair Range
$22.24 -
$24.78
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$2.23
(10.3%)
Support & Resistance Levels
Support Level
$21.40
Resistance Level
$24.44
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.47
Wall Street Target
$45.18
(+108.3%)
Revenue Growth (YoY)
2.6%
Earnings Growth (YoY)
153.1%
Profit Margin
-52.7%
Valuation Discount vs History
-7.9% cheaper
PE vs Historical
5.5 vs 7.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.9%
(market-implied from PE analysis)
1-Year Target
$19.98
(-8%)
2-Year Target
$18.40
(-15%)
3-Year Target
$16.94
(-22%)
3-Yr Target (if PE normalizes)
(PE: 5→7)
$21.69
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 10.0%)
$118.04
(+444%)
Base:
(SPY PE: 5.5, Growth: 10.0%)
$28.88
(+33%)
Bear:
(PE: 4.6, Growth: 10.0%)
$24.55
(+13%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.5 to 7.0
Stabilization Target:
$27.77
(+28.0%)
PE Expansion Potential:
+28.0%
Share & Embed Analysis
Last updated: March 31, 2026 2:11 AM ET
Data refreshes hourly during market hours. Next update: 3:11 AM
Data refreshes hourly during market hours. Next update: 3:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENOV showing a specific setup today?
Insider Activity (6 Months)
7
Buys
2
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Oliver Engert
BUY
1000 shares
2026-03-13
Oliver Engert
BUY
1000 shares
2026-03-09
Oliver Engert
BUY
750 shares
2026-03-06
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 56 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 51 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$354 | 48 HOLD |
